Company Overview and News

Air Selangor denies special treatment for Splash

2018-08-10 theedgemarkets
SHAH ALAM (Aug 10): Pengurusan Air Selangor Sdn Bhd (Air Selangor) has denied allegations that it gives special treatment to Syarikat Pengeluar Air Sungai Selangor (Splash) when it offered the company an acquisition value of RM2.55 billion on Aug 3.

Air Selangor denies claim Splash purchase overpriced

2018-08-10 malaymail
KUALA LUMPUR, Aug 10 — Pengurusan Air Selangor (Air Selangor) today refuted former Selangor Mentri Besar Tan Sri Khalid Ibrahim’s claim that its offer to acquire Syarikat Pengeluar Air Selangor Holdings (Splash) for RM2.55 billion was 10 times more than the value of the company.

Air Selangor denies SPLASH bought at 10 times its price

2018-08-10 theedgemarkets
KUALA LUMPUR (Aug 10): Pengurusan Air Selangor Sdn Bhd has denied that the Selangor state government is paying 10 times the price to buy over water concessionaire Syarikat Pengeluar Air Selangor (SPLASH).

Pimpinan Ehsan sees 22.08% stake traded off-market at discount

2018-08-06 theedgemarkets
KUALA LUMPUR (Aug 6): Pimpinan Ehsan Bhd saw 15.27 million of its shares, or a 22.08% stake, cross off-market today, at a discount of nearly 5%.

Stock With Momentum: Puncak Niaga Holdings

2018-08-06 theedgemarkets
Trading in the shares of Puncak Niaga Holdings Bhd (fundamental: 1.35/3, valuation: 1.2/3) triggered our momentum algorithm for the second time since July 4.

KLCI reverses loss but broader sentiment stays tepid

2018-07-31 theedgemarkets
KUALA LUMPUR (July 31): The FBM KLCI reversed its earlier losses at the midday break today, lifted by select index-linked blue chips, but the broader market sentiment remained tepid, tracking regional markets.
7083 HLFBF 1082 5032 NFLX BATS 4162 3794 9334 6033 7277 2852 PNADF 5225 3301 3867 4723 Q0F IHHHF 6807 PNAGF 1929

KLCI pares loss but seen staying in the red, tracking region

2018-07-31 theedgemarkets
KUALA LUMPUR (July 31): The FBM KLCI pared some of its losses at mid-morning today but looked poised to end the session in the red as regional markets remained weak.
7083 6491 7251 7060 4065 BC94 SMSN BATS 4162 7237 3034 3794 9334 6033 7123 2852 PNADF 3867 6807 PNAGF SMSD

Puncak Niaga appoints Zainal Abidin Salleh as new MD

2018-07-18 theedgemarkets
KUALA LUMPUR (July 18): Puncak Niaga Holdings Bhd has appointed Datuk Zainal Abidin Salleh as its new managing director, effective immediately.

KPS bags pipeworks contract worth RM20m from Air Selangor

2018-07-03 theedgemarkets
KUALA LUMPUR: Kumpulan Perangsang Selangor Bhd (KPS) has secured a contract worth RM20 million from Pengurusan Air Selangor Sdn Bhd to replace existing pipeworks in Hulu Langat and Kuala Lumpur.
5843 BSMAF 6807 1818

Contract win sends Puncak shares up 6.5%

KUALA LUMPUR: Shares of Puncak Niaga Holdings Bhd gained 6.5% in early trade Friday on the back of a RM490mil contract win from Jalur Cahaya Sdn Bhd.

Trading ideas: Puncak Niaga, F&N, DGB Asia

KUALA LUMPUR:JF Apex Research expects Puncak Niaga Holdings Bhd , Fraser & Neave Holdings Bhd (F&N) and DGB Asia Bhd to generate trading interest following its latest corporate news.
6807 0152

Selangor likely to get another extension in takeover bid

What an opening: Devamany (fifth from left), Zaini (fourth from left), UBM Malaysia co-chairman Tan Sri Mohd Azumi Mohamed (third from right) and other VIPs pouring water into a large tank at the official opening of AsiaWater 2018 at KLCC.
5843 6807

Selangor MB fails RM14m countersuit against Puncak Niaga

2018-03-15 themalaymailonline
The High Court dismissed Datuk Seri Mohamed Azmin Ali’s counter-claim with costs of RM3,000 after finding there was no cause of action against Puncak Niaga. — Picture by Choo Choy MaySHAH ALAM, March 15 ― The High Court here today dismissed a counter-claim by Selangor Mentri Besar Datuk Seri Mohamed Azmin Ali in an almost RM14 million suit filed by Puncak Niaga Holdings Bhd (Puncak Niaga) over the restructuring of the state’s water industry.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...